- NorthStar Medical Radioisotopes will support PDRadiopharma, a PeptiDream subsidiary, with R&D services and supply of actinium-225 for peptide-RI conjugate programs.
- The collaboration includes contract development, manufacturing services, and a focus on PeptiDream’s CA9 cancer therapeutic.
NorthStar Medical Radioisotopes and PeptiDream Inc. have entered a strategic collaboration to advance peptide-RI conjugate programs, focusing initially on PDRadiopharma’s CA9 therapeutic asset. PDRadiopharma, a radiopharmaceuticals company in Japan and a wholly owned subsidiary of PeptiDream, will gain access to NorthStar’s advanced R&D and contract manufacturing capabilities under the agreement.
Under the collaboration agreement, NorthStar will:
- Initiate R&D services for PDRadiopharma’s lead therapeutic asset, 225Ac-CA9 (225Ac-PD-32766).
- Leverage its state-of-the-art development and manufacturing facility to supply Ac-225 and produce patient doses of diagnostic and therapeutic products for PDRadiopharma’s clinical trials.
- Conduct research and development to advance PDRadiopharma’s pipeline of radiopharmaceutical programs further.
The collaboration will involve NorthStar’s provision of actinium-225 (Ac-225), essential for the development of novel diagnostics and therapeutics, alongside manufacturing support for clinical trial doses. Dr. Masato Murakami, PDRadiopharma’s President, highlighted the alliance’s potential to accelerate innovative cancer treatments, stating, “Our agreements with NorthStar… will be an important part of our efforts to bring new medicines to patients.”
Founded in 1968, PDRadiopharma has pioneered radiopharmaceuticals for SPECT and PET imaging and now focuses on advancing next-generation diagnostics and therapies. NorthStar’s CEO, Frank Scholz, praised PeptiDream’s scientific leadership, emphasising the importance of this partnership in making transformative treatments a reality.
